|
A study released in San Antonio in December 2004. It stated that 10% of women who have bc and are being treated with Herceptin have brain mets as their INITIALmetathesis.
"Other investigators analyzed the occurrence of CNS metastasis as the first site of progression in the pivotal trial as well as other studies of first-line trastuzumab-based treatment for advanced breast cancer.[5] Isolated CNS metastasis occurred in roughly 10% of patients receiving first-line trastuzumab-based therapy. Progression in the CNS tended to occur later than progression at other sites of disease. Treatment with trastuzumab did not in and of itself increase the risk of CNS disease; in fact, it appeared protective during the first 7 months of therapy. Finally, comparing HER2 tumors positive by fluorescence in situ hybridization (FISH) vs those negative by FISH suggested that FISH-positive tumors have a predisposition for CNS recurrence from the time of primary breast cancer diagnosis."
Regards
Joe
|